Rothwell Figg

Latest from Rothwell Figg - Page 2

The U.K. released a National AI Strategy with a ten-year plan to make Britain a global AI superpower in our new age of artificial intelligence.  The Strategy intends to “signal to the world [the U.K.’s] intention to build the most
Continue Reading The U.K. National AI Strategy Begins with Consultations on Copyright, Patent, and Data Protection Regime

On September 16, 2021, eleven congressional leaders (“the Signors”) sent a letter to Andrew Hirshfeld, the acting director of the United States Patent and Trademark Office (“USPTO”), requesting the USPTO to reevaluate the Patent Trial and Appeal Board’s (“PTAB”) view
Continue Reading Key Members of Congress Urge USPTO to Curtail Discretionary Denials of IPR Petitions to Help Lower Drug Costs by Breaking Patent Thickets

On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop and commercialize a potential gene therapy drug developed by Regenxbio for treating age-related macular degeneration (wet AMD), diabetic retinopathy, and
Continue Reading Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy